Boston Scientific Q2 net sales $4.12B (+14.5% reported), adj EPS $0.62, above guidance; acquires Silk Road Medical

BOSTON SCIENTIFIC CORP

2024-Q2 EPS reported $0.55 revenue$7,977,000,000

Q2 net sales $4.120B, up 14.5% reported (16.1% operational, 14.7% organic); GAAP EPS $0.22, adjusted EPS $0.62 vs guidance $0.57-$0.59.
Cardiovascular segment sales grew 17.8% reported; MedSurg grew 9.0%; U.S. sales up 16.9%.
Received China NMPA approval for FARAPULSE PFA System; launched AGENT Drug-Coated Balloon in U.S. and received China NMPA approval.
Announced agreement to acquire Silk Road Medical (SILK) for stroke prevention; subject to customary closing conditions.
FY2024 guidance: reported sales growth 13.5-14.5%, adj EPS $2.38-$2.42; Q3 guidance: adj EPS $0.57-$0.59.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.